Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir

Swiss Association for the Study of the Liver, and Moradpour D, Helbling B. and Cerny A, De Gottardi A. and Heim MH, Majno P. and Müllhaupt B, Negro F. and Rubbia-Brandt L, Semela D. and Vilei SB, Bernsmeier C. and Bihl F, Borovicka J. and Dill M, Dufour J. F. and Filipowicz M, Geier A. and Gerlach T, Giostra E. and Gonvers JJ, Goossens N. and Gubler C, Hadengue A. and Heim MH, Helbling B. and Hellstern M, Hirschi C. and Jochum W, Krähenbühl S. and Kullak-Ublick G, Lange C. and Lavanchy D, Majno P. and Malinverni R, McLin V. and Mentha G, Mertens J. C. and Nasser S, Oneta C. and Pache I, Rubbia-Brandt L. and Sauter B, Semela D. and Spahr L, Steuerwald M. and Stickel F, Stieger B. and Wehr K, Zala G.. (2012) Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir. Swiss medical weekly, Vol. 142 , w13516.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6419978

Downloads: Statistics Overview


Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates to ~70% and allows to shorten treatment duration in ~½ of treatment-naïve patients with chronic hepatitis C genotype 1. Sustained virological response rates in treatment-experienced patients depend on the response to previous treatment, ranging from <80% in previous relapsers to ~30% in previous null responders. These advances come at the expense of new adverse effects and increased cost. In addition, treatment of chronic hepatitis C will become more complex. In these times of changing medical practice, the present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Pharmacology (Krähenbühl)
UniBasel Contributors:Krähenbühl, Stephan
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Note:Publication type according to Uni Basel Research Database: Journal item
Related URLs:
Identification Number:
Last Modified:02 Oct 2015 10:00
Deposited On:02 Oct 2015 10:00

Repository Staff Only: item control page